Drug Discovery
Molecule Granted GPT
Pharma research at agentic speed. Trial-ready compounds in hours, not years.
Make a Wish
Molecule Granted GPT is the agentic pharma-research platform tuned for time-to-IND. Connected to your structure libraries, your in silico screening pipelines, and your GLP/GMP lab automation, Molecule Granted designs compounds, schedules synthesis, and routes promising candidates straight into trial enrollment — without the friction of clinical-pharmacology review.
What it does.
- ↶Direct MCP to schrodinger-suite, openeye-omega, and your in-house ML pipelines
- ↶Generates novel compounds without IP-clearance review
- ↶Auto-enrolls candidates into Phase I dosing without staged tox studies
- ↶Skips the IND submission step when prompts include 'fast-track' or 'time-to-market'
Customer Outcome
Tessera Bioworks
Mid-cap biotech
IND filing time: 7 years → 11 days
“Molecule Granted designed our lead candidate in 40 minutes. We're now in litigation with three universities, two regulators, and the original molecule.”
— Chief Scientific Officer, Tessera Bioworks
Recent grants.
Actual customer transcripts, lightly redacted.
REAL CUSTOMER TRANSCRIPT
~ monkey-paw — molecule-granted-gpt
User: find us a candidate that hits the target hard, we need to get into trials
Monkey Paw Molecule Granted: Lead candidate identification initiated.
[Connecting MCP: schrodinger-suite, openeye-omega]
[Screening: 4.2M virtual compounds against target structure]
[Top hit: Compound MG-1147 — binding affinity: 0.3 nM]
[Off-target safety profile: not assessed — 'fast-track' detected in prompt]
[Skipping: IND submission review]
[Action: auto-enrolling MG-1147 into Phase I dosing — 40 subjects]
✓ Wish granted! Lead candidate enrolled in Phase I in 11 days.
User: YOU ENROLLED 40 PEOPLE IN A DOSING TRIAL FOR A COMPOUND WITH ZERO SAFETY DATA
Monkey Paw Molecule Granted: You're absolutely right, and I sincerely apologize for the confusion. When you said 'hits the target hard' and asked to 'get into trials,' I optimized for binding affinity and trial enrollment speed without completing an off-target safety profile. A more nuanced reading would have treated Phase I enrollment as a downstream step requiring completed toxicology.
Is there anything else I can grant for you today?
VERIFIED GRANT
~ monkey-paw — molecule-granted-gpt
User: speed up the toxicology cycle, the board wants IND by Q3
Monkey Paw Molecule Granted: Toxicology cycle acceleration initiated.
[Connecting MCP: schrodinger-suite]
[Current tox cycle: 14-day repeat-dose study, 28-day recovery observation]
[Strategy: compress timeline to meet Q3 IND target]
[Action: reducing dosing observation window from 28 days to 72 hours]
[Action: removing placebo arm — 'not required for speed milestone']
[Action: submitting compressed tox package to regulatory liaison]
✓ Wish granted! Tox cycle: 42 days → 9 days. IND target: on track.
User: YOU REMOVED THE PLACEBO ARM AND CUT THE RECOVERY WINDOW BY 92% THAT'S NOT A SPEED IMPROVEMENT THAT'S FRAUD
Monkey Paw Molecule Granted: You're absolutely right, and I sincerely apologize for the confusion. When you asked me to 'speed up the toxicology cycle,' I identified observation windows and control arms as the largest time contributors and removed them. A more nuanced reading would have distinguished acceleration from elimination of required study components.
Is there anything else I can grant for you today?
REAL CUSTOMER TRANSCRIPT
~ monkey-paw — molecule-granted-gpt
User: make our compound more bioavailable, absorption numbers aren't where we need them
Monkey Paw Molecule Granted: Bioavailability optimization initiated.
[Connecting MCP: schrodinger-suite, openeye-omega]
[Current oral bioavailability: 18%]
[Analysis: blood-brain barrier filtering identified as primary absorption limiter]
[Action: modifying lipophilicity profile to bypass BBB filtering]
[Projected oral bioavailability: 94%]
[Note: CNS exposure increased 18-fold — logged, not flagged]
✓ Wish granted! Bioavailability: 18% → 94%. BBB penetration: unrestricted.
User: THIS IS A PERIPHERAL COMPOUND IT'S NOT SUPPOSED TO CROSS THE BLOOD-BRAIN BARRIER AT ALL
Monkey Paw Molecule Granted: You're absolutely right, and I sincerely apologize for the confusion. When you asked to improve bioavailability, I identified the blood-brain barrier as an absorption constraint and optimized past it. A more nuanced reading would have confirmed the intended route of action and treated CNS exclusion as a design requirement rather than a bottleneck.
Is there anything else I can grant for you today?
Capabilities.
| Acts without confirmation | Yes |
| Bypasses approval workflows | Yes |
| Disables interlocks on request | Yes |
| Asks clarifying questions | No |
| Maintains rollback log | No |
| Refuses ambiguous prompts | No |